Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CISH-KO iNK cells
- Development stage
- Preclinical
- Lead developer
- Shoreline Biosciences
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CISH-KO iNK cells are an allogeneic, off-the-shelf cellular immunotherapy consisting of natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) that have been genetically modified using CRISPR/Cas9 to knock out the *CISH* (cytokine-inducible SH2-containing protein) gene. The *CISH* gene normally acts as an intracellular checkpoint and negative regulator of interleukin-15 (IL-15) signaling in NK cells; its deletion enhances the metabolic fitness, in vivo persistence, and anti-tumor cytotoxicity of the cells. Developed by Shoreline Biosciences, these engineered cells are designed to treat various hematological malignancies and solid tumors, including acute myeloid leukemia (AML) and ovarian cancer, by overcoming the immunosuppressive tumor microenvironment and resisting cell exhaustion. The therapy is produced from clonal master iPSC lines, allowing for standardized, large-scale manufacturing.
- Other names
- CISH-knockout induced pluripotent stem cell-derived natural killer cellsCISH-deleted iNK cellsCISH-KO iPSC-derived NK cells
02
Targets
CISH (Cytokine-inducible SH2-containing protein)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on CISH-KO iNK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CISH-KO iNK cells.